July 17, 2017 / 10:45 AM / 5 days ago

BRIEF-Repros Therapeutics ‍expects to receive European patent ‍​

1 Min Read

July 17 (Reuters) - Repros Therapeutics Inc:

* Repros Therapeutics Inc - ‍expects to receive European patent that relates to selective progesterone modulators​

* Repros Therapeutics Inc - ‍repros assessing uterine fibroid and endometriosis development program with vaginal drug delivery treatment​

* Repros - ‍FDA indicated that company will be required to compile a large pre-approval safety data base to support future development of proellex program​

* Repros Therapeutics Inc - proellex development program will remain on partial clinical hold by FDA​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below